Fate Therapeutics, Inc.
FATE
$0.9205
-$0.0458-4.74%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -78.55% | -87.34% | -89.67% | -95.27% | -34.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -78.55% | -87.34% | -89.67% | -95.27% | -34.03% |
| Cost of Revenue | -24.59% | -48.33% | -57.07% | -60.60% | -50.95% |
| Gross Profit | -12.01% | 14.30% | 31.87% | 33.80% | 58.22% |
| SG&A Expenses | -6.42% | 8.41% | 3.07% | 12.10% | 14.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.66% | -32.91% | -42.47% | -45.05% | -37.22% |
| Operating Income | -2.64% | 4.96% | 19.20% | 18.87% | 38.22% |
| Income Before Tax | -15.74% | -2.92% | 16.94% | 19.10% | 42.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.74% | -2.92% | 16.94% | 19.10% | 42.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.74% | -2.92% | 16.94% | 19.10% | 42.88% |
| EBIT | -2.64% | 4.96% | 19.20% | 18.87% | 38.22% |
| EBITDA | -2.52% | 5.86% | 21.72% | 21.53% | 41.54% |
| EPS Basic | -0.92% | 6.37% | 21.30% | 20.82% | 43.83% |
| Normalized Basic EPS | 12.14% | 6.03% | 20.77% | 16.88% | 40.50% |
| EPS Diluted | -0.92% | 6.40% | 21.32% | 20.84% | 43.84% |
| Normalized Diluted EPS | 12.14% | 6.03% | 20.77% | 16.88% | 40.50% |
| Average Basic Shares Outstanding | 15.37% | 10.89% | 6.41% | 1.97% | 1.64% |
| Average Diluted Shares Outstanding | 15.37% | 10.89% | 6.41% | 1.97% | 1.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
